Sebastián Chiavenna

Sebastián Chiavenna began their career in 2002 as a PhD Fellow at the Virology Institute, INTA, where they worked on Bovine Viral Diarrhea Virus (BVDV). In 2008, they joined Ferrer as Senior Corporate Marketing Manager, where they later became Head of Project Development and Medical Advisor for Biotechnology. In 2020, they became a Senior Associate - Life Science Investment Funds at Caixa Capital Risc and a Board Director at GlyCardial Diagnostics. In 2022, they became a Board Director at Inbiomotion SL.

Sebastián Chiavenna's education history includes a Bachelor of Science degree from the University of Buenos Aires, which they obtained from 1996 to 2002. Sebastián then earned a Master of Business Administration from EAE Business School from 2013 to 2015. In 2012, they completed a Clinical Trials Monitoring course at Colegi Oficial de Metges de Barcelona. Sebastián also holds a Doctor of Philosophy from the University of Buenos Aires, which they earned from 2002 to 2007. In 2019, they completed a Change and Marketing Leadership program at Esade. Sebastián also holds additional certifications in BSc, MBA, and PhD from the Universidad de Buenos Aires.